Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Policy / Regulatory

New Guidelines for Advanced Gastric Cancer Drug Development Released in China

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) of China has published the “Guidance Principles for Clinical...

Company Drug

Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study

Fineline Cube Feb 14, 2025

US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...

Company Drug

Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment

Fineline Cube Feb 14, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...

Company

GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials

Fineline Cube Feb 14, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) released its...

Company Drug

Betta Pharma Files for EMA Approval of ALK Inhibitor Ensartinib

Fineline Cube Feb 14, 2025

Betta Pharmaceuticals (SHE: 300558) announced the initiation of a market approval filing with the European...

Company Deals Drug

Lee Kai and Yangshun Partner on Polyvinyl Alcohol Embolization Microspheres

Fineline Cube Feb 14, 2025

Chinese companies Shanghai Lee Kai Technology Co., Ltd (Kai Medtech) and Hangzhou Yangshun Medical Technology...

Company Deals

Nanos Medical Raises Over RMB300m to Boost Otolaryngology Device Lead

Fineline Cube Feb 14, 2025

China-based Nanos Medical (Shanghai) Limited, an otolaryngology device maker, has reportedly raised over RMB300 million...

Company Drug

SciClone’s Vibativ Approved by NMPA for HABP/VABP Treatment

Fineline Cube Feb 14, 2025

China-based SciClone Pharmaceuticals Inc. announced that it has received market approval from the National Medical...

Company Deals

Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA

Fineline Cube Feb 14, 2025

China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody...

Policy / Regulatory

NMPA Releases 90th Batch of Reference Drugs for GQCE

Fineline Cube Feb 14, 2025

The National Medical Products Administration (NMPA) has released the 90th batch of reference drugs for...

Company Drug

Accropeutics Doses First Patient in AC-101 Phase Ib UC Study

Fineline Cube Feb 14, 2025

Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...

Policy / Regulatory

China Launches Major Public Health Initiatives to Enhance Healthcare Accessibility

Fineline Cube Feb 14, 2025

In a bid to bolster public health infrastructure and improve healthcare services, China’s National Health...

Company Drug

Sanofi and J&J’s E. coli Vaccine Fails Phase III Study

Fineline Cube Feb 14, 2025

France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate...

Company Drug

Antengene’s Xpovio Included in Taiwan’s NHI Drug List for Myeloma Treatment

Fineline Cube Feb 14, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first...

Company Deals

Boehringer Ingelheim Partners with ExpressionEdits on Gene Therapy Tech

Fineline Cube Feb 14, 2025

German pharmaceutical giant Boehringer Ingelheim has entered into a collaboration and licensing agreement with UK-based...

Company Drug

Merck’s Zerbaxa Approved by China’s NMPA for Complex Infections

Fineline Cube Feb 14, 2025

US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that it has...

Policy / Regulatory

Hainan Unveils Biomedical New Technology Policy to Boost Medical Innovation

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Hainan’s Biomedical New Technology PolicyThe Hainan Provincial Health Commission,...

Company Drug

Roche’s Evrysdi Tablet Approved by FDA for Spinal Muscular Atrophy

Fineline Cube Feb 13, 2025

Swiss giant Roche (SWX: ROG) has announced that it has received marketing approval from the...

Policy / Regulatory

Shanghai’s Ambitious Plan to Revolutionize Brain-Computer Interfaces

Fineline Cube Feb 13, 2025

In-Depth Analysis and Orientation Guide for Shanghai’s Brain-Computer Interface (BCI) PolicyShanghai has unveiled a groundbreaking...

Company Drug

Pfizer’s Adcetris Gets New FDA Approval for Lymphoma Treatment

Fineline Cube Feb 13, 2025

US giant Pfizer (NYSE: PFE) has announced that it has received another indication approval from...

Posts pagination

1 … 265 266 267 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.